| scholarly article | Q13442814 |
| P2093 | author name string | Wen-Hao Su | |
| Ming-Hung Hu | |||
| Yuen-Liang Lai | |||
| Jeng-Fong Chiou | |||
| Ming-Yuan Huang | |||
| Shen-Chi Wu | |||
| Wei-Yong Chiang | |||
| Tsung-Yu Yen | |||
| P2860 | cites work | Morphine and alternative opioids in cancer pain: the EAPC recommendations | Q24648711 |
| Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). | Q32147934 | ||
| A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials | Q33273642 | ||
| Breakthrough pain: definition, prevalence and characteristics | Q33435886 | ||
| Absorption and tolerability of fentanyl buccal soluble film (FBSF) in patients with cancer in the presence of oral mucositis | Q35221603 | ||
| Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain | Q36609652 | ||
| The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. | Q37245357 | ||
| Long-term safety and tolerability of fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic pain: an 18-month study | Q37769317 | ||
| Treatment of breakthrough pain with fentanyl buccal tablet in opioid-tolerant patients with chronic pain: appropriate patient selection and management | Q37774033 | ||
| Breakthrough pain in cancer patients: prevalence, mechanisms and treatment options | Q38564494 | ||
| Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care | Q38586530 | ||
| Fentanyl Buccal Soluble Film: A Review in Breakthrough Cancer Pain | Q38786011 | ||
| A randomized, double-blind, placebo-controlled study of fentanyl buccal tablets for breakthrough pain: efficacy and safety in Japanese cancer patients | Q39219511 | ||
| The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting | Q39229449 | ||
| A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer | Q39344435 | ||
| Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. | Q42504553 | ||
| Intra- and interindividual variabilities in the pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a cross-study analysis | Q44042032 | ||
| A report on the long-term use of fentanyl pectin nasal spray in patients with recurrent breakthrough pain | Q44272068 | ||
| Opioid prescribing: guidelines, laws, rules, regulations, policies, best practices | Q44341861 | ||
| Dose proportionality and pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a phase I, open-label, three-period, crossover study | Q48199095 | ||
| Fentanyl buccal soluble film (Onsolis) for breakthrough cancer pain | Q84082963 | ||
| P433 | issue | 30 | |
| P921 | main subject | cancer pain | Q3712728 |
| P304 | page(s) | e11593 | |
| P577 | publication date | 2018-07-01 | |
| P1433 | published in | Medicine | Q15716652 |
| P1476 | title | Proportional dose of rapid-onset opioid in breakthrough cancer pain management: An open-label, multicenter study | |
| P478 | volume | 97 |
| Q98154714 | A dose titration study of fentanyl buccal soluble film for breakthrough cancer pain in Taiwan | cites work | P2860 |
Search more.